{
    "sec_cik": "0001578845",
    "sec_company_name": "Actavis plc (Filer)",
    "document_type": "EX991",
    "sec_form_header": "Form 8-K",
    "sec_period_of_report": "20150123",
    "sec_filing_date": "20150129",
    "sec_changed_date": "20150129",
    "sec_accepted_date": "20150129161807",
    "sec_index_url": "https://www.sec.gov//Archives/edgar/data/1578845/000119312515025590/0001193125-15-025590-index.htm",
    "sec_url": "https://www.sec.gov//Archives/edgar/data/1578845/000119312515025590/0001193125-15-025590.txt",
    "metadata_file_name": "C:\Users\aaron\OneDrive\Desktop\homework\finance2\SEC-EDGAR-text\output_files_examples\batch_0004\004\AGN_0001578845_EX991_20150123_EX-99_metadata.json",
    "original_file_name": "",
    "original_file_size": "14250 chars",
    "document_group": "EX-99",
    "section_name": "EX-99",
    "section_n_characters": 6061,
    "endpoints": [
        "EX-99.1   ",
        "Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Actavis’ current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Actavis disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Actavis’ current expectations depending upon a number of factors affecting Actavis’ business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Actavis’ products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Actavis’ periodic public filings with the Securities and Exchange Commission, including but not limited to Actavis’ Quarterly Report on Form 10-Q for the quarter ended September 30, 2014. Except as expressly required by law, Actavis disclaims any intent or obligation to update these forward-looking statements."
    ],
    "extraction_method": "html",
    "warnings": [],
    "company_description": "AGN",
    "output_file": "C:\Users\aaron\OneDrive\Desktop\homework\finance2\SEC-EDGAR-text\output_files_examples\batch_0004\004\AGN_0001578845_EX991_20150123_EX-99_excerpt.txt",
    "time_elapsed": 0.0,
    "batch_number": 4,
    "batch_signature": "",
    "batch_start_time": "2023-04-16 21:15:41.037609",
    "batch_machine_id": "DESKTOP-BTCJU5K",
    "section_end_time": "2023-04-16 21:27:20.045390"
}